Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419
SAN DIEGO, CA, USA I January 22, 2025 I Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the potential to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain.
“We are pleased to be ushering our lead candidate, CG001419, into a second clinical trial as planned. This protein degrader program is now in clinical testing in two different indications,” said Dr. Ying Luo, Chairman and CEO of Cullgen. “Cullgen has successfully generated a portfolio of multiple, highly active, selective, and bioavailable targeted protein degrader compounds. Exploration of these molecules across therapeutic disciplines aligns with our goal of becoming a leader in the pursuit of the next generation of targeted protein degraders.”
Cullgen received ethics committee approval in Australia to begin enrollment into the Phase 1 healthy volunteer study (NCT06636500). The trial is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose/food-effect and multiple-ascending-dose study of orally administered CG001419. The study is designed to evaluate the safety, tolerability and pharmacokinetic characteristics of CG001419.
As previously announced, Cullgen entered into a merger agreement with Pulmatrix, Inc. (Nasdaq: PULM) on November 13, 2024. Subject to the terms and conditions of the merger agreement, and upon the closing of the merger, the combined company which will operate under the name Cullgen Inc., be headquartered in San Diego, CA and trade on The Nasdaq Capital Market (Nasdaq).
About Cullgen Inc.
Cullgen is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. The Company applies its proprietary uSMITE™ (ubiquitin-mediated, small molecule -induced target elimination) platform technology to build the next generation of targeted protein degraders and degrader-antibody conjugates (“DACs”). Cullgen’s mission is to utilize its proprietary platform to expand the drug design paradigm beyond functional site inhibition, enabling the targeting of historically “undruggable” proteins for selective destruction. Leveraging years of work by its founders on the proteasome system and key discoveries regarding its functionality, Cullgen has successfully generated multiple highly active, selective, and bioavailable targeted protein degrader compounds. Cullgen is also actively advancing several of its highly active degraders as payloads for use in degrader-antibody conjugates (DACs). For more information, visit www.cullgen.com.
SOURCE: Cullgen
Post Views: 102
Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419
SAN DIEGO, CA, USA I January 22, 2025 I Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the potential to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain.
“We are pleased to be ushering our lead candidate, CG001419, into a second clinical trial as planned. This protein degrader program is now in clinical testing in two different indications,” said Dr. Ying Luo, Chairman and CEO of Cullgen. “Cullgen has successfully generated a portfolio of multiple, highly active, selective, and bioavailable targeted protein degrader compounds. Exploration of these molecules across therapeutic disciplines aligns with our goal of becoming a leader in the pursuit of the next generation of targeted protein degraders.”
Cullgen received ethics committee approval in Australia to begin enrollment into the Phase 1 healthy volunteer study (NCT06636500). The trial is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose/food-effect and multiple-ascending-dose study of orally administered CG001419. The study is designed to evaluate the safety, tolerability and pharmacokinetic characteristics of CG001419.
As previously announced, Cullgen entered into a merger agreement with Pulmatrix, Inc. (Nasdaq: PULM) on November 13, 2024. Subject to the terms and conditions of the merger agreement, and upon the closing of the merger, the combined company which will operate under the name Cullgen Inc., be headquartered in San Diego, CA and trade on The Nasdaq Capital Market (Nasdaq).
About Cullgen Inc.
Cullgen is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. The Company applies its proprietary uSMITE™ (ubiquitin-mediated, small molecule -induced target elimination) platform technology to build the next generation of targeted protein degraders and degrader-antibody conjugates (“DACs”). Cullgen’s mission is to utilize its proprietary platform to expand the drug design paradigm beyond functional site inhibition, enabling the targeting of historically “undruggable” proteins for selective destruction. Leveraging years of work by its founders on the proteasome system and key discoveries regarding its functionality, Cullgen has successfully generated multiple highly active, selective, and bioavailable targeted protein degrader compounds. Cullgen is also actively advancing several of its highly active degraders as payloads for use in degrader-antibody conjugates (DACs). For more information, visit www.cullgen.com.
SOURCE: Cullgen
Post Views: 102
